| Revenue growth | H1 +18% to Rs 512 Cr; Q2 +19% to Rs 264 Cr |
|---|---|
| Margins | Adj. EBITDA 13.7% H1 (+51bps); reported 10.9% (-179bps) |
| Demand visibility | IPM volume +2.3%; CDMO share-of-wallet gains cited |
| Management confidence | Confident tone; cites 15 straight record quarters |
Growth
H1 revenue +18% to Rs 512 Cr; Q2 +19% to Rs 264 Cr. Adj. EBITDA +23%, adj. PAT +33%.
Outlook
No numeric growth guidance. Plant-6 commercialised Sep-26; injectables and P-2 extension in progress; ~20% payout target.
Risks
Trade Generics down 31% on codeine product exit; reported PAT flat; ESOP charges rising to Rs 14 Cr in H1.
Last quarter's promises, checked
Delivered
- Plant-6 full commercial by end-H1 → commercialised Sep-26 (= BEAT)
- 14 straight record-revenue qtrs → 15 straight (= BEAT)
Partly delivered
- Injectables 'back on track' → CDMO +32% H1, injectables not disclosed separately (= PARTIAL)
- Plant-6 'fully online' after validations → commercialised; no ramp/utilisation data (= PARTIAL)
Missed
- TG momentum back in 'few quarters' → TG -31% H1 post codeine exit (= MISS)
Investor Presentation filed with BSE, NSE: WINDLAS. Summary written with AI assistance from the document.
Windlas Biotech Ltd: key numbers
- Share price
- ₹921.25
- Market cap
- ₹1,934 Cr
- Revenue (annual)
- ₹904.1 Cr
- Net profit (annual)
- ₹66.44 Cr
- P/E (TTM)
- 29.1×Sector 37.9×
- Promoter holding
- 63.31%+0.00% QoQ
- FII holding
- 2.09%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Windlas Biotech Ltd
All →Windlas Biotech Management Change
Windlass Biotech reports Mr. Ashok Kumar Windlass ceased as Executive Director, resigning for succession planning, effective 5 November 2026. He moves to Founder President, and Hitesh Windlass becomes Managing Director.
Windlas Biotech Results Update
Windlas Biotech reported H1 FY27 revenue of Rs 512 crore, up 18% YoY. Adjusted PAT rose 33% to Rs 50 crore for the half year.
Windlas Biotech Q2 FY27 Results: Net Profit ₹18.1 Cr, Up 1.7% YoY
Windlas Biotech Ltd reported revenue from operations of ₹263.9 Cr (+18.7% YoY) and net profit of ₹18.1 Cr (+1.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹18.1 Cr · +1.7% YoY
Windlas Biotech Adverse Business Impact
Windlas Biotech disclosed a cyber security incident on 30 October 2026. It states no material impact on core operations, finances or business continuity.
Windlas Biotech Board Meeting Date
Windlas Biotech intimated that its Board meeting is scheduled for 5 November 2026 to consider unaudited standalone results for Q1 FY27. No monetary figure is disclosed in this advance notice.
Windlas Biotech Other Announcement
This quarterly shareholding pattern statement for Windlas Biotech Ltd, covering the period ended September 30, 2026, provides the company's equity ownership breakdown.